This promotional video has been sponsored by Accord Healthcare, and is intended for an international audience of healthcare professionals (HCPs).
The products mentioned may not be registered in all countries. Prescribing information may vary per country. HCPs must refer to their country prescribing information.

Orgovyx▼ and Camcevi have extended indications in the UK:
Orgovyx▼(relugolix) UK prescribing information can be found here.
Camcevi (leuprolide) UK prescribing information can be found here.
Degarelix UK SmPC with legal classification and price can be found here. 

Orgovyx▼ (relugolix) EU SmPC with legal classification can be found here.
Camcevi (leuprolide) EU SmPC with legal classification can be found here.
Degarelix EU SmPC with legal classification can be found here. 

Orgovyx▼ EU indication: Orgovyx is indicated for the treatment of adult patients with advanced metastatic hormone-sensitive prostate cancer.
Cardiovascular disease such as myocardial infarction and stroke has been reported in the medical literature in patients with androgen deprivation therapy. Therefore, all cardiovascular risk factors should be taken into account. 
The most commonly observed adverse reactions during relugolix therapy are physiological effects of testosterone suppression, including hot flushes (54%), musculoskeletal pain (30%), and fatigue (26%). Other very common adverse reactions include diarrhoea and constipation (12% each).

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.